Avis et décisions de la HAS
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
Voir aussi
Avis et décisions de la HAS
17/11/2017
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
QqGkSHyC9HejeHZ7
Écouter
